David Rintell is the Head of Patient Advocacy at QED Therapeutics and BridgeBio Pharma. His focus is on strengthening ties with patient advocacy organizations, and implementing the BridgeBio core value of Putting Patients First. Prior to joining BridgeBio, Dr. Rintell was the Head of Global Patient Advocacy, Rare Diseases, at Sanofi Genzyme in Cambridge, MA. At Genzyme, he led an international team working with patient organizations in lysosomal storage disorders, genetic ocular diseases, and hATTR Amyloidosis. Prior to working in the biotech industry, he held clinical appointments at two Harvard Medical School affiliated hospitals, the Massachusetts General Hospital and the Brigham and Women’s Hospital, where as a clinical psychologist, he focused on the assessment and treatment of patients with chronic diseases and their families with a specialization in Multiple Sclerosis in adults and children. He was also on the faculty of Brandeis University’s graduate program in genetic counselling, training the future professionals who will help families understand genetic conditions. He served several patient advocacy organizations in as a board member, member of clinical advisory committees, and as a volunteer. His many publications focus on the psychosocial impact of medical illness, and psychosocial adaptation to chronic medical illness. He is a Clinical Instructor in Psychiatry at Harvard Medical School, and Professor of the Practice Emeritus, Brandeis University.